Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
4 Oct 24
8-K
Entry into a Material Definitive Agreement
4 Oct 24
10-Q
2024 Q3
Quarterly report
9 Aug 24
8-K
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
9 Aug 24
8-K
Regulation FD Disclosure
24 Jun 24
S-8
Registration of securities for employees
31 May 24
8-K
Departure of Directors or Certain Officers
30 May 24
10-Q
2024 Q2
Quarterly report
10 May 24
8-K
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
10 May 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
10-Q
2024 Q1
Quarterly report
9 Feb 24
8-K
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
9 Feb 24
10-K
2023 FY
Annual report
15 Dec 23
8-K
Edesa Biotech Reports Fiscal Year 2023 Results
15 Dec 23
8-K
Other Events
26 Oct 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
8-K
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
12 Oct 23
8-K
Edesa Biotech Announces One-for-Seven Reverse Share Split
11 Oct 23
10-Q
2023 Q3
Quarterly report
9 Aug 23
8-K
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
9 Aug 23
8-K
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
27 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jun 23
S-8
Registration of securities for employees
24 May 23
8-K
Departure of Directors or Certain Officers
24 May 23
10-Q
2023 Q2
Quarterly report
11 May 23
8-K
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
11 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
DEF 14A
Definitive proxy
28 Mar 23
8-K
Entry into a Material Definitive Agreement
27 Mar 23
424B5
Prospectus supplement for primary offering
27 Mar 23
10-K/A
2022 FY
Annual report (amended)
27 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
10-Q
2023 Q1
Quarterly report
10 Feb 23
8-K
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
10 Feb 23
EFFECT
Notice of effectiveness
27 Dec 22
424B3
Prospectus supplement
23 Dec 22
CORRESP
Correspondence with SEC
21 Dec 22
UPLOAD
Letter from SEC
21 Dec 22
Latest ownership filings
4
Pardeep Nijhawan
2 Oct 24
4
Pardeep Nijhawan
3 Sep 24
4
Pardeep Nijhawan
2 Aug 24
4
Pardeep Nijhawan
3 Jul 24
4
Pardeep Nijhawan
4 Jun 24
SC 13G
SATTERFIELD THOMAS A JR
3 Jun 24
4
Pardeep Nijhawan
1 May 24
4
Pardeep Nijhawan
2 Apr 24
4
Pardeep Nijhawan
25 Mar 24
4
Pardeep Nijhawan
1 Mar 24
4
Pardeep Nijhawan
2 Feb 24
SC 13G/A
Velan Capital Investment Management LP
29 Jan 24
SC 13D/A
Pardeep Nijhawan Medicine Professional Corp
16 Jan 24
4
Pardeep Nijhawan
12 Jan 24
SC 13D/A
Pardeep Nijhawan Medicine Professional Corp
21 Aug 23
4
Stephen Lemieux
4 Aug 23
4
Michael J Brooks
4 Aug 23
4
Pardeep Nijhawan
4 Aug 23
4/A
Charles V Olson
24 Jul 23
4/A
Michael J Brooks
24 Jul 23
4/A
Joan Chypyha
24 Jul 23
4/A
Carlo Sistilli
24 Jul 23
4/A
FRANK R. OAKES
24 Jul 23
4/A
Sean Arthur MacDonald
24 Jul 23
4/A
Patrick Marshall
24 Jul 23
4/A
Pardeep Nijhawan
24 Jul 23
4/A
Stephen Lemieux
24 Jul 23
4
Pardeep Nijhawan
21 Jul 23
4
Stephen Lemieux
21 Jul 23
4
Michael J Brooks
21 Jul 23
4
Patrick Marshall
21 Jul 23
4
Sean Arthur MacDonald
21 Jul 23
4
Joan Chypyha
21 Jul 23
4
FRANK R. OAKES
21 Jul 23
4
Charles V Olson
21 Jul 23
4
Carlo Sistilli
21 Jul 23
3
Stephen Lemieux
17 Jul 23
3
Charles V Olson
24 May 23
3
Joan Chypyha
24 May 23
3
Patrick Marshall
24 May 23